Introduction
============

Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease of unknown etiology. The evolution of the disease is unpredictable. Most patients follow a chronic course and have flare-ups or exacerbations, with a number of hospital admissions.

Hypothesis and objectives
=========================

The use of Rituximab (RTX) decrease the hospital admissions in SLE patients refractory to immunosuppressive therapy.

Material and methods
====================

This is an observational, retrospective and multicenter study. Sequential observation was made at baseline, at 24^th^ week and final visit. The outcome variables were: clinic improvement measured by SLEDAI, Physician's Global Assessment (PGA) and patient hospitalization for SLE during the 24^th^ week and final visit. Statistical analysis of the qualitative and quantitative variables was done by Chi-square and T-test/Wolcoxon, respectively.

Results
=======

We treated 46 patients (94% women), mean age 36.50 ± 11.47 ages, 91% Caucasians.

Monitoring: mean of 21,1±13,9 months. The main reason for use of RTX was: nephritis (24%,) arthritis (28%), thrombocytopenia (11%), neurological (13%), cutaneous (13%) and others (11%).

The most common dose used was 2x1g (87%). The median of cycles was 2 (rank 1-3). Patients treated with RTX improved SLEDAI, PGA and reduced hospital admissions (table [1](#T1){ref-type="table"}).

###### 

Endpoints.

                                   Baseline          24th week            Final Visit
  -------------------------------- ----------------- -------------------- --------------------
  SLEDAI (0--105), median (rank)   14.5 (7.8-22.3)   4.0 (2.0--6.0)\*\*   2.0 (0.0--4.0)\*\*
  PGA (0--3), median (rank)        2.8 (2.0--3.0)    0.0 (0.0--1.0)\*\*   0.0 (0.0-1.0)
  Hospitalization, n (%)           25 (54%)          1 (2.3%)\*\*         2 (4%)\*\*

\*\*p \<0,0005 respect to baseline.

Conclusions
===========

RTX may be effective in SLE patients refractory to immunosuppressive therapy, as it gets to control disease activity and reduces hospital admissions. For these reasons, RTX should be considered a therapeutic option of first choice in these patients.
